Talafil Drug Interactions

Organic Nitrates and Nitric Oxide Donors: Administration of tadalafil to patients who are using any form of organic nitrate is contraindicated. Based on pharmacodynamic interaction were potential increase in hypotensive effect. Additive effects was observed when sublingual nitroglycerin followed a tadalafil dose, with most effects no longer detectable after 48 hours.
Drug affecting hepatic microsomal enzymes: Tadalafil does not appear to induce or inhibit the clearance of other drugs metabolized by CYP isoform CYP3A4, CYP1A2, CYP2D6, CYP2E1, CYP2C9 and CYP2C19.
Warfarin: No clinical effect on pharmacokinetic and pharmacodynamic of warfarin. Tadalafil had no effect on S- or R-warfarin, nor did affect changes in prothrombin time induced by warfarin.
Aspirin: No clinical effect on pharmacodynamic such as alteration bleeding time caused by aspirin.
Antihypertensive Agents: Potentiation of hypotensive effect based on pharmacodynamic interaction with antihypertensive agents (alpha-adrenergic blocking agents, angiotensin II receptor antagonists, amlodipine, enalapril, metoprolol). In some patients, concomitant use of tadalafil and alpha-adrenergic blocking agents can lower blood pressure.
Alcohol: No clinical effect on the pharmacokinetics of tadalafil and alcohol plasma concentration. In addition, coadministration of tadalafil and alcohol may produce postural dizziness and orthostatic hypotension.
Theophylline: Potential pharmacodynamic interaction. The only small effect is theophylline-induced increase in heart rate.
H2-antagonist: Nizatidine had no clinically effects on pharmacokinetics.
Antacid: Coadministration of tadalafil and antacids reduced the rate of tadalafil absorption without altering the AUC.